Featuring perspectives from Drs Muhamed Baljevic, Joseph Mikhael and Nina Shah, moderated by Dr Robert Z Orlowski. Published October 12, 2021. (Webinar Video Proceedings)
TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
CE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS: CME credit is no longer available for this issue
NURSES: NCPD credit is no longer available for this issue
FOR SUCCESSFUL COMPLETION
Video Program: This activity consists of a video component.
CME/NCPD credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
Muhamed Baljevic, MD
Assistant Professor of Medicine
Division of Hematology/Oncology, Department of Internal Medicine
Fred and Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska
Advisory Boards: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation; Research Support: Amgen Inc, Exelixis Inc.
Joseph Mikhael, MD
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Phoenix, Arizona
Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc.
Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology Oncology
University of California, San Francisco
San Francisco, California
Consulting Agreements: Amgen Inc, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Kite, A Gilead Company, Oncopeptides, Sanofi Genzyme; Contracted Research: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Sutro Biopharma, TeneoBio.
Moderator
Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Advisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board).
UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS —The below planning committee members have nothing to disclose:
Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC— RTP Reviewer, and Kathryn Ault Ziel, PhD—RTP Staff and Planner.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Oncopeptides and Takeda Oncology.
Release date: October 20, 2021
Expiration date: October 20, 2022
(WIFI is recommended for best performance):